For laboratory research use only — not for human or veterinary use. Not evaluated by the U.S. FDA.
Metabolic Peptide
Survodutide
A dual glucagon and GLP-1 receptor agonist investigated in clinical research for metabolic regulation and body composition.
Quantity
$109.99
Bundle & save
Delivery
Order by 3:00 PM ET for same-day dispatch
Cutoff 3:00 PM ET · same-day dispatch
Estimated arrival in 2–3 business days
Overnight shipping available
Free shipment protection included
Survodutide
1 × 10mg · $109.99
99% purity, QC passed
HPLC + mass-spec verified
Shipment protection
Free on every order
Free shipping over $150
Same-day dispatch before 3PM ET
Certificate of Analysis
Third-party tested · Independent analytical lab
10mg
99.28%latest
| Tested | Measured | Purity |
|---|---|---|
| Jun 2026 | 11.86mg | 99.28% |
| Oct 2025 | 10.90mg | 99.89% |
Frequently researched together
Commonly studied alongside Survodutide.
Compound information
Technical specifications
Molecular profile
| Type | Glucagon / GLP-1 receptor dual agonist |
| CAS number | 2805997-46-8 |
| Molecular weight | 4232 g/mol |
| Formula | C192H289N47O61 |
Storage & stability
- ❄️
Lyophilized (powder)
-20°C · stable 2+ years
- ❄️
Reconstituted
2–8°C · use within 30 days
Sources & references
Peer-reviewed literature, for research context
- The lancet. Diabetes & endocrinology
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
2024·DOI: 10.1016/S2213-8587(23)00356-X·PMID: 38330987le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hennige AM
View source - The New England journal of medicine
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
2024·DOI: 10.1056/NEJMoa2401755·PMID: 38847460Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E
View source - Molecular metabolism
BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
2022·DOI: 10.1016/j.molmet.2022.101633·PMID: 36356832Zimmermann T, Thomas L, Baader-Pagler T, Haebel P, Simon E, Reindl W
View source - Diabetologia
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label GLP-1 (S) in people with type 2 diabetes: a randomised clinical trial
2024·DOI: 10.1007/s00125-023-06053-9·PMID: 38095657Blüher M, Rosenstock J, Hoefler J, Manuel R, Hennige AM
View source
Important research notice
Not for human consumption. This product is sold exclusively for laboratory and in vitro research. It is not intended to diagnose, treat, cure, or prevent any disease.
Any research findings referenced on this page are drawn from published, peer-reviewed literature and are provided for educational context only. They are not product claims and should not be read as medical advice.
By purchasing, you confirm you are a qualified researcher and will handle this material in accordance with all applicable laws and institutional guidelines.